CURRICULUM VITAE
Mohan Suntharalingam, MD, MBA
The Marlene and Stewart Greenebaum
Professor of Radiation Oncology
University of Maryland School of Medicine
DATE:
March, 2014
OFFICE ADDRESS
University of Maryland School of Medicine
Department of Radiation Oncology
22 S. Greene Street, GGK0101
Baltimore, MD 21201
E-mail: msuntha@umm.edu
(410) 328-2331
(410) 328-6911 fax
CURRENT ADMINISTRATIVE ROLE
President & CEO
UMMS/St. Joseph Medical Center
Vice President for System Program Development
University of Maryland Medical System
EDUCATION
1982 - 1986
A.B. – Human Biology (Biology & Psychology) – Brown University
Providence, Rhode Island
1986 - 1990
M.D. – Jefferson Medical College – Philadelphia, PA
2007 – 2009
MBA – The Wharton School of Business - University of Pennsylvania
Philadelphia, PA.
POST GRADUATE TRAINING
1990 – 1991
Internship in Internal Medicine, Bryn Mawr Hospital
Bryn Mawr, Pennsylvania
1991 – 1993
Resident in the Department of Radiation Oncology
University of Maryland Medical Systems – Baltimore, MD
1
POST GRADUATE TRAINING – Continued
1993 – 1994
Chief Resident in the Department of Radiation Oncology
University of Maryland Medical Systems – Baltimore, MD
1994 – 1995
Clinical Oncology Fellow of the American Cancer Society
University of Maryland Medical Systems – Baltimore, MD
SUB-SPECIALTY ROTATION DURING RESIDENCY TRAINING
1/93
Breast Service, Department of Radiation Oncology
Thomas Jefferson University Hospital
Philadelphia, PA
3/94
Head and Neck Service, Department of Radiation Oncology
University of Florida, Gainesville, FL
5/94
Pediatric Service, Department of Radiation Oncology
St. Jude Children’s Research Hospital
Memphis, TN
3/95
Conformal Therapy Research Program
Christie Hospital, Manchester, England
Royal Marsden Hospital, London, England
CERTIFICATION
6/91
Diplomat of the National Board of Medical Examiner
6/95
Certification in Radiation Oncology by the American Board of Radiology
5/05
Re-Certification in Radiation Oncology by the American Board of Radiology
LICENSE
Maryland License #: D0047618
FACULTY APPOINTMENTS
7/95 – 6/01
Assistant Professor
Department of Radiation Oncology
University of Maryland School of Medicine
7/01 – 6/04
Associate Professor
Department of Radiation Oncology
University of Maryland School of Medicine
7/04 – 7/06
Associate Professor with Tenure
Department of Radiation Oncology
University of Maryland School of Medicine
7/06 – Present
Professor with Tenure
Department of Radiation Oncology
University of Maryland School of Medicine
2
ADMINISTRATIVE APPOINTMENTS
8/97 – 12/12
Vice Chairman
Department of Radiation Oncology
University of Maryland School of Medicine
1/03 – 1/06
Associate Director for Multidisciplinary Program Development and Outreach
University of Maryland Marlene and Stewart Greenebaum Cancer Center
1/06 – 12/12
Associate Director of Clinical Affairs, University of Maryland
Marlene and Stewart Greenebaum Cancer Center
7/06 – Present
Director Program of Excellence in Technology Based Translational Research
Department of Radiation Oncology
University of Maryland School of Medicine
(Direct oversight of a planned $5 million endowed research program)
3/08 – Present
Associate Director Radiation Oncology Residency Program
University of Maryland Medical System
3/08 – 07/09
Director - Program of Excellence in Technology Based Translational Research
Department of Radiation Oncology
University of Maryland School of Medicine
CLINICAL APPOINTMENTS
7/95 – Present
Member, Program in Oncology
University of Maryland Marlene and Stewart Greenebaum Cancer Center
10/95 – 8/97
Acting Clinical Director
Department of Radiation Oncology
University of Maryland School of Medicine
8/97 – 12/12
Clinical Director
Department of Radiation Oncology
University of Maryland School of Medicine
6/02 – 9/08
Medical Director
Department of Radiation Oncology
Baltimore Washington Medical Center
1/03 – 9/09
Director of Clinical/Translational Research
Department of Radiation Oncology
University of Maryland School of Medicine
PROFESSIONAL MEMBERSHIPS





1986 – Present
1991 – 1995
1991 – 1995
1991 – Present
1991 – Present
The Omega Psi Phi Fraternity
American Medical Association Member
Association of Residents in Radiation Oncology
American College of Radiation Oncology
American Society for Therapeutic Radiology and Oncology
3
PROFESSIONAL MEMBERSHIPS - Continued




1995 – Present
1997 – Present
2000
2000
Simon Kramer Society (Vice Chairman)
Radiation Therapy Oncology Group
American College of Radiology
American Radium Society
AWARDS & HONORS

1988 – 1990
Amory Hare Medical Honor Society

1995
Clinical Oncology fellowship in Conformal Therapy, Sponsored by The
American College of Radiation Oncology

1999
Nominated for the Lane W. Adams Award sponsored by The American
Cancer Society

2005
Best Doctors in America, Best Doctors, Inc.

2007
Best Doctors in America, Best Doctors, Inc.

2007
Top Doctors, Baltimore Magazine

2008
Endowed Professorship, University of Maryland Marlene and Stewart
Greenebaum Cancer Center

2009-2010
Best Doctors in America, Best Doctors, Inc.
INSTITUTIONAL COMMITTEES
1996
Member – CALGB Clinical Research Committee
University of Maryland Marlene and Stewart Greenebaum Cancer Center
1996
Member – Oncology Network Development and Implementation Team
University of Maryland Medical Center
1997
Member – Clinical Productivity Design Team
Office of the Dean, University of Maryland at Baltimore
1996 - 1997
Member – Search Committee, Deputy Director for Clinical Affairs
University of Maryland Marlene and Stewart Greenebaum Cancer Center
1996 - 1999
Director, Esophageal Cancer Section, Thoracic Malignancy Task Force
University of Maryland Marlene and Stewart Greenebaum Cancer Center
1996 - Present
Member – University of Maryland School of Medicine Council
1996 - Present
Member – Clinical Research Committee
University of Maryland Marlene and Stewart Greenebaum Cancer Center
1996 - Present
Member – Cancer Committee, University of Maryland Marlene and Stewart
Greenebaum Cancer Center.
4
INSTITUTIONAL COMMITTEES – Continued
1996 - 2000
Member, Baltimore VA Medical Center Cancer Committee
1996 - 2000
Member – Total Body Irradiation Task Force
Department of Radiation Oncology
University of Maryland School of Medicine
1998 - Present
Member – Cancer Review Committee
University of Maryland Marlene and Stewart Greenebaum Cancer Center
Member – Cancer Center Research Council
University of Maryland Marlene and Stewart Greenebaum Cancer Center
2002 - Present
2002
Member – Cancer Council
University of Maryland Marlene and Stewart Greenebaum Cancer Center
2003
Member – Dean’s Search Committee for Position of Chairman of the Department of
Otolaryngology, University of Maryland School of Medicine
2003 - Present
Member – Bicentennial Planning Committee, University of Maryland School of
Medicine
2004 - Present
Member – Ambulatory Care Project Opening Group
University of Maryland Medical Center
2007
LCME Institutional Self Study Educational Resources Subcommittee
2007
Member - Commitment to Excellence Committee – Physician Partnership Group
University of Maryland Medical Center
EDITORIAL POSITIONS
1995 – Present
Ad hoc reviewer, International Journal of Radiation Oncology Biology Physics
1997 – Present
Ad hoc reviewer, Cancer
1999 – Present
Ad hoc reviewer, Journal of Clinical Oncology
2005 - Present
Editorial Board, Cancer Investigation
2006 – Present
Editorial Board, Journal of Surgical Oncology
EDUCATIONAL / TEACHING ACTIVITIES
1991 – Present
Medical Student Education-Monthly Lecturer in Clinical Radiation
Oncology for Rotating Medical Students
2-4 hours/month
1993 – 1994
Coordinator of Education Program For Residents in Radiation Oncology
1993 – 1995
Coordinator, Grand Rounds/Visiting Professor Lectureship schedule of
The University of Maryland School of Medicine, Department of
Radiation Oncology
1995 – Present
Weekly Multidisciplinary Thoracic Malignancy Conference – 1 hr/wk
5
EDUCATIONAL / TEACHING ACTIVITIES – Continued
1995 – Present
Radiation Oncology Resident Research Preceptor
2 hrs/week
1995 – Present
Radiation Oncology Resident Education
Annual lectures in Clinical Radiation Oncology
Morning quality assurance/teaching conference
Monday Journal Club
Mock Oral Board Examiner
8 hrs/week
1995 – Present
Departmental Advisor/Research Mentor for Medical Students Entering
the field of Radiation Oncology
1996 – Present
Otolaryngology Resident Education
Annual lectures in Clinical Radiation Oncology
3 hrs/year
1997 – Present
Gastroenterology Fellow Education
Annual lecture in Clinical Radiation Oncology
2 hrs/year
2001 – Present
Medical Director of University of Maryland Dosimetry School (one of six certified
programs in the country)
2-4 hrs/month
2004 - 2008
Question Writer for National In-Service exam for Radiation Oncology Residents in
Training Exam (head and neck cancer section)
2010
Oral Board Examiner - Invited. American Board of Radiology (Head & Neck Cancer
Section)
MEDICAL STUDENT MENTORSHIP
MEDICAL STUDENTS
CLASS
RESIDENCY PROGRAM
Michael Garofalo
Joseph Herman
Zach Fowler
Selma Jabbour
Vladimir Ioffe
Suneel Nada
Igor Poltinnkov
Josh Petit
Anil Dhople
Ashish Patel
Todd Flannery
Steven Ronson
Pinaki Dutta
Suzannah Yavino
Jerry Jaboin
1999
2000
2000
2001
2001
2001
2001
2002
2002
2003
2003
2004
2004
2005
2005
University of Chicago
University of Michigan
Emory University
Johns Hopkins Hospital
Eastern Virginia Medical School
Rush Presbyterian
Thomas Jefferson Medical College
Massachusetts General Hospital
University of Maryland Medical System
Thomas Jefferson Medical College
University of Maryland Medical System
Loma Linda University
University of Pennsylvania
University of Maryland Medical System
Vanderbilt University
Total time dedicated to direct teaching activities – 20-25% effort.
6
NATIONAL CLINICAL RESEARCH
1995 – Present
Committee Member, Radiation Oncology
Cancer and Leukemia Group B (CALGB) National Cooperative Study Group.
Sponsored by The National Cancer Institute.
1996 – Present
Principal Investigator University of Maryland School of Medicine (Full Member
Institution), Radiation Oncology Therapy Group (RTOG) National Cooperative Study
Group. Sponsored by the National Cancer Institute.
(Funding: $75-100,000/year)
Status: Ongoing
1998 – Present
Principal Investigator (Radiation Oncologist)
The Stents and Radiation Therapy Trial (START). Forty-center, National Registry
Trial Evaluating the Use of Brachytherapy for In-Stent Coronary Artery Restenosis.
Sponsored by the Novoste Corporation.
Funding: $120,000 total cost
Study: Study closed.
1998 – Present
University of Maryland Physician Representative
Elekta Oncology International Research Corsortium
1999 – Present
Patterns of Care Study Esophageal Cancer Committee Member;
Review Committee studying National Standards of Radiotherapy Practice for
Esophageal Cancer. Sponsored by the American College of Radiology and the
National Cancer Institute.
Funding: $60,000 total cost
Status: Study closed.
1999 – Present
Principal Investigator (Radiation Oncologist)
Stents and Radiation Therapy Trial (START 40) 50 Center National Collaborative
Trial Evaluating the use of a 40 mm Source Train in the Management of In-Stent
Coronary Artery Restenosis. Sponsored by the Novoste Corporation.
2001 – Present
Thoracic Malignancies Steering Committee, Radiation Therapy Oncology Group
Gastrointestinal Disease Site Steering Committee, Radiation Therapy Oncology
Group.
2002 – Present
Patterns of Care Study Representative to the American College of Surgeons for the
Joint Evaluation of National Standards of Practice for Esophageal Cancer. Sponsored
by the National Cancer Institute.
2003 – Present
Principal Investigator RTOG L-0229
A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and High
Dose Radiotherapy Followed by Surgical Resection, and Consolidative Therapy for
Locally Advanced Non-Small Cell Lung Carcinoma.
Multi-Institutional, Phase II Trial
Status: Opened 10/04
2003 – Present
Vice Chairman, Radiation Therapy Oncology Group
Member of the Executive Steering Committee of Radiation Therapy Oncology Group
Chairman, Membership Committee, Radiation Therapy Oncology Group
NCI Grant No. CA 21661 (5% effort with support).
7
NATIONAL CLINICAL RESEARCH – Continued
2004 - Present
Head and Neck Malignancies Steering Committee, Radiation Therapy Oncology
Group.
2004 – Present
Principal Investigator RTOG 0436
A Phase III Trial Evaluating the Addition of Cetuximab to Weekly Paclitaxel, Cisplatin,
and Daily Radiation for Patients with Locally Advanced Esophageal Cancer.
Multi-Institutional, Phase III Randomized Trial
Status: Open 7/2008, accruing patients
2007
Co-Investigator NIH RO1 Grant
Feedback Control of Respiration Induced Tumor Motion with a Treatment Couch
This study will determine the feasibility of a real-time respiration induced tumor
Motion-synchronized treatment couch that will negate the displacement of the
tumor during radiation delivery and the development and testing of an inferential
model to predict the location of the tumor as a function of the respiration cycle.
Funding: $1,416,175, 1% effort on this grant.
2007
Co-Investigator NIH R21 Grant
Feedback Control and Inferential Modeling for Radiotherapy Treatment Couch
This study has enabled the design and development of the prototype treatment
couch and it has determined the dosimetric feasibility of controlling tumor motion
by moving the couch in three dimensions.
Funding: $273,194, 1% effort on this grant.
INVESTIGATOR INITIATED CLINICAL RESEARCH PROTOCOLS
1996 Principal Investigator: The Role of Tirapazamine (SR4233) in Radiotherapy. New Investigator
Award/Intramural Award; University of Maryland School of Medicine.
Funding: $15,000
1998 Institutional Principal Investigator: Novoste sponsored BetaCath Trial of Intravascular Radiation to
Prevent Coronary Artery Restenosis.
Funding: $80,000 total cost
Status: Study closed, accrual complete
1998 Institutional Principal Investigator: Stent or Radiation Therapy Intervention for Esophageal Cancer
Dysphasia (SORTIE) Plan, Multi-Center Trial Comparing Stents Versus External Beam Radiation for
Palliation in Esophageal Cancer Patients. Sponsored by Boston Scientific.
Funding: $20,000 total cost
Status: Study closed, accrual complete
1999 (IRB #0799205) Principal Investigator: Phase I/II Feasibility Study of Intensity Modulated Radiation
Therapy for Newly Diagnosed Cancer Patients. Sponsored by Elekta Corporation.
Funding: $20,000
Status: Study closed, accrual complete
1999 Principal Investigator: A Phase I Study of UFT and Hydroxyurea Plus Hyperfractionated Reirradiation Therapy for Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck.
Sponsored by Bristol-Myers Squibb.
Funding: $60,000
Status: Study Closed, accrual complete
8
INVESTIGATOR INITIATED CLINICAL RESEARCH PROTOCOLS - Continued
1999 (GCC #98-39) Principal Investigator: A Phase I Study of Paclitaxel, UFT, Leucovorin and Radiation
Therapy for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Sponsored by Roche Pharmaceuticals.
Funding: $60,000
Status: Study closed, accrual complete
2000 (GCC #99-67) Principal Investigator: Cisplatin, 5-FU and Accelerated Hyperfractionation with a
Concomitant Boost Followed by Surgical Resection then Docetaxel Chemotherapy for Patients
Presenting with Locally Advanced Esophageal Carcinoma. Sponsored by Adventis Pharmaceuticals.
Funding: $250,000
Status: Study closed, accrual complete
2000 (GCC #00-67) Institutional Principal Investigator: A Multinational, Multicenter, Double-Blind,
Placebo Controlled, Randomized, Phase III, Clinical Trial to Determine the Efficacy and Safety of IB-367
Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck
Malignancies. Sponsored by Intrabiotics Corporation.
Funding: $20,000
Status: Closed.
2000 Principal Investigator: The Predictive Value of Thymidylate Synthase, Thymidine Phosphorylase,
and Dihydropyrimidine Dehydrogenase in Chemoradiation Strategies for Squamous Cell Carcinoma of
the Head and Neck. Sponsored by Roche Pharmaceuticals.
Funding: $142,000
2001 (GCC #00-14) Principal Investigator: A Phase I Study of Docetaxel, Carboplatin, and Accelerated
Fractionation with Concomitant Boost Radiation Therapy for Patients with Advanced Loco-Regional
Squamous Cell Carcinomas of the Head and Neck. Sponsored by Adventis Pharmaceuticals.
Funding: $64,500 direct costs
Status: Study closed to accrual.
2002 (GCC #02-02) Principal Investigator: A Single Site Evaluation of Amifostine for Mucosal and
Hermopoetic Protection, and Concurrent Carboplatin, Paclitaxel and Radiotherapy in the Management of
Patients with Advanced Loco-Regional Squamous Cell Carcinomas of the Head and Neck. Sponsored by
Medimmune, Inc.
Funding: $68,700 direct costs
Status: Study closed, accrual complete.
2003 Principal Investigator: Non-Operative Therapy of Local Regional Carcinoma of the Esophagus. A
Phase II Study of Paclitaxel, Carboplatin and Radiotherapy. Sponsored by Bristol-Myers Squibb
Oncology.
Funding: $123,750 total costs
Status: Study closed
2004 (GCC #04-43) Co-Principal Investigator: Cetuximab, Paclitaxel, Carboplatin and Radiation for
Esophageal Gastroesophageal Junction and Gastric Cancer Multicenter Trial Including, Brown University,
and University of Maryland. Sponsored by Bristol-Myers Squibb Oncology.
Funding: $250,000 total costs
Status: Study closed; accrual complete.
2004 – Present (GCC #04-42) Principal Investigator: A Phase II Study of Evaluation of Cetuximab
(ERBITUX) and Concurrent Carboplatin, Paclitaxel and Radiotherapy in the Management of Patients with
Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck. Sponsored by Bristol-Myers
Squibb Oncology.
Funding: $302,709 total costs
Status: Study open, accruing patients.
9
INVESTIGATOR INITIATED CLINICAL RESEARCH PROTOCOLS - Continued
2008 – (GCC #07-40) Principal Investigator: Neoadjuvant Paclitaxel Poliglumex (PPX;CT-2103),
Cisplatin and Radiation for Esophageal Cancer: Multicenter Trial including Brown University and
University of Maryland. Sponsored by Cell Therapeutics, Inc.
Funding: $100,754 total costs
Status: Open, accruing patients
2009 – (NIH-R01) Co-principal Investigator: Radiotherapy with Dose-Rate Regulated Tracking
Total funding requested: $1,595,674
PUBLICATIONS – JOURNAL ARTICLES
1. Galkin, B., Feig, S., Mieur H., Suntharalingam, M. Photomicrographics of Breast Calcification
Correlation with Histopathological Diagnosis. Radiographics, 3:3, 450-477, 1985.
2. Espinoza-Jacobs, M., Suntharalingam, M., et al. Combined Carbo Platinum CBDCA-Bleomycin
(BLEO) and Conventional Radiotherapy for Advanced Unresectable Squamous Cell Carcinoma of the
Head and Neck, American Journal of Clinical Oncology, 18:1, 52-55, 1995.
3. Suntharalingam, M., Rudoltz, M.S., Mendenhall, W.H., Parsons, J.T., Stringer, S.P., Million, R.R.
The Role of Radiotherapy in the Management of Merkel Cell Carcinoma of the Skin on the Head and
Neck. Head and Neck, 17, 96-101, 1995.
4. Rhee, J.G., Eddy, H.A., Hong, J.J., Suntharalingam, M., Vaupel, P.W. Divergent Changes of
Diameter and Flow through Individual Blood Vessels Upon Localized Heating. Int. J. Hyperthermia,
12:6, 757-769, 1996.
5. Um, K., Cheston, S., Suntharalingam, M., Rhee, J. Reduced Adriamycin Cytotoxicity in RIF-1 MultiCell Spheroid Due to an Acidic Microenvironment. Environmental Mutagens and Carcinogins. 17:1,
7-11, 1997.
6. Conley, B., Jacobs, M., Suntharalingam, M., Zacharski, D., Ord, R., Gray, W., Aisner, J. The Role of
Paclitaxel/Carboplatin and Concurrent Radiotherapy in Unresectable Squamous Cell Carcinoma of
the Head and Neck. Seminars in Radiation Oncology. 7:2, Supp (1), 139-141, 1997.
7. Conley, B., Jacobs, M., Suntharalingam, M., Zacharski, D., Ord, R., Gray, W., Aisner, J. A Pilot Trial
of Paclitaxel, Carboplatin and Concurrent Radiotherapy for Unresectable Squamous Cell Carcinoma
of the Head and Neck. Seminars in Oncology, 24:1, Supp. (2), 787-780, 1997.
8. Sonett, J., Krasna, M., Suntharalingam, M., Doyle, A., Scheutz, J., McLaughlin, J. Interior TrapDoor Surgical Approach for Advanced Stage Lung Cancer Following Neoadjuvant Chemotherapy and
Radiotherapy. Penn Assoc Thor Surg, 6, 51-55, 1998.
9. Rhee, J., Liu, J., Suntharalingam, M. Halo Comet Assay Triage of Irradiated Personnel. Armed
Forces Radiobiology Research Institute, D5-9, 1998.
10. Sonett, J.R., Krasna, M.J., Suntharalingam, M., Scheutz, J., Gamliel, Z., McLaughlin, J. Safe
Pulmonary Resection After Chemotherapy and High Dose Thoracic Radiation. Annals of Thoracic
Surgery, 68, 316-320, 1999.
11. Krasna, M.J., Mao, Y.S., Sonett, J.R., Tamura, G., Jones, R., Suntharalingam, M., Meltzer, S.F.
P53 Gene Protein Expression Predicts Response and Survival in Esophageal Cancer Patients
Treated by Tri-Modality Therapy. Annals of Thoracic Surgery, 68, 2021-2025, 1999.
10
PUBLICATIONS – JOURNAL ARTICLES – Continued
12. Li, X.A., Wang, R, Yu C, Suntharalingam, M. Beta versus Gamma for Catheter-Based Intravascular
Brachytherapy: Dosimetric Perspectives in the Presence of Metallic Stents and Calcified Plaques.
Int. J. Radiation Oncology, Biol. Phys. 46,4: 1043-1049, 2000.
13. Suntharalingam, M, Haas, M, Conley, BA, Egorin, MJ, Levy, SG, Herman JM, Jacobs, MC, Gray,
WC, Ord, RA, Aisner, J, Van Echo, DA. Radiation Therapy with Concurrent Weekly, Carboplatin and
Paclitaxel in Advanced Stage Unresectable Squamous Cell Carcinomas of the Head and Neck. Int.
J. Radiat Oncol Biol Phys, 47(1):49-56, 2000.
14. Suntharalingam, M, Sonett JR, Haas ML, Doyle LA, Hausner, PF, Schuetz J, Krasna MJ. The Use
of Concurrent Chemotherapy with High Dose Radiation Prior to Surgical Resection in Patients
Presenting with Apical Sulcus Tumors. The Cancer Journal of the Scientific American, 6,6:365-371.
2000.
15. Suntharalingam, M. Radiation Therapy for Esophageal Cancer. Chest Surgery Clinics of North
America, 10:3, 569-581, 2000.
16. Suntharalingam, M. , Haas, M.L., Van Echo, D.A., Haddad, R., Jacobs, M.C., Levy, S., Gray, W.C..,
Ord, R.A., Conley, B.A. Predictors of Response and Survival Following Concurrent Chemotherapy
and Radiation for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Cancer, 91,
448-554, 2001.
17. Lee, Y.C., Chen, J.C., Amoscato, A.A., Bennouna, J., Spitz, D.R., Suntharalingam, M., Rhee, J.G.
Protective Role of BCL-2 in Metabolic Oxidative Stress-Induced Cell Death. J of Cell Science, 114:4,
677-684, 2001.
18. Li, X.A., Suntharalingam, M. Dosimetry of Source Stepping for Intravascular Brachytherapy.
Cardiovasc Radiat Med, 2:3, 165-172, 2001.
19. Suntharalingam, M., Haas, M., Sonett, J., Doyle, L.A., Hausner, P.F., Schuetz, J., Greenwald,B.,
Krasna, M.J. Accurate Lymph Node Assessment Prior to Trimodality Therapy for Esophageal
Carcinoma. The Cancer Journal of the Scientific American, 7(6), 509-511, 2001.
20. Suntharalingam, M. Innovations in the Radiotherapy of Head and Neck Cancer, Veterans Health
System Journal, 6:3, 54-58, 2001.
21. Jiao, X., Krasna, M.J., Sonett, J., Gamliel, Z., Suntharalingam, M., Doyle, A., Greenwald, B. PreTreatment Surgical Lymph Node Staging Predicts Results of Trimodality Therapy in Esophageal
Cancer. European J of Cardio-Thoracic Surgery, 19, 880-886, 2001.
22. Ma, L., Yu, C.X., Earl, M., Holmes, T., Safaraz, M., Li, X.A., Shepard, D., Amin, P.A., DiBiase, S.,
Suntharalingam, M., Mansfield, C.M. Optimized Intensity Modulated Arc Therapy for Prostate
Cancer. Int J Cancer, 96, 379-384, 2001.
23. Li, B., Yu, J., Suntharalingam, M., Kennedy, A.S., Amin, P.A, Chen, Z., Yin, R., Guo, S., Han T.,
Wang, Y, Yu, N., Song, G., Wong, L. Comparison of Three Treatment Options for Single Brain
Metastasis from Lung Cancer. Int J Cancer, 90:1, 37-45, 2002.
24. Jiao, X., Sonett, J., Gamliel, Z., Doyle, A., Schuetz, J., Greenwald, B., Suntharalingam, M., Krasna,
M.J. Trimodality Treatment versus Surgery Alone for Esophageal Cancer. A Stratified Analysis with
Minimally Invasive Pretreatment Staging. J of Cardiovascular Surgery, 43(4) 531-7, August 2002.
25. Song, J.J. Rhee, J.G., Suntharalingam, M., Walsh, S.A., Spitz, D.R., Lee, Y.J. Role of Glutaredoxin
in Notabolic Oxidative Stress. Glutaredoxin as a Sensor of Oxidative Stress Medicated by H 202.
Journal of Biochemistry, 277 (48); 465-75, November 2002.
11
PUBLICATIONS – JOURNAL ARTICLES – Continued
26. Yu, X.A., Li, A.X., Ma, L., Chen, D., Naqvi, S., Shepard, D., Safaraz, M., Holmes, T.,
Suntharalingam, M., Mansfield, C.M. Clinical Implementation of Intensity Modulated Arc Therapy.
International Journal of Radiation Oncology, Biology and Physics, 53:2, 453-463, 2002.
27. Suntharalingam, M., Laskey, W., Lansky, A.J., Waksman, R., White, L., Teirstien, P., Massulio, Va.,
Rutherford, B., Elman, A., Kuntz, R.E., Popma, J.J., Bonan, R. START 40 Investigators. Clinical and
Angiographic Outcomes After Use of 90Strontium/90Yttrium Beta Radiation for the Treatment of InStent Restenosis: Results from the Stents and Radiation Therapy 40(START 40) Registry.
International Journal of Radiation Oncology, Biology and Physics, 52:4, 1075-1082, 2002.
28. Popma, J.J., Suntharalingam, M., Lansky, A.J., Heuser, R.R., Speiser, B., Teirstrein, P.S., Massullo,
V., Bass, T., Henderson, R., Silber, S., von Rottkay, P., Bonan, R., Ho, K.H.K, Kuntz, R. A
Randomized Trial of 90Strontium/90Yttrium Beta Radiation Versus Placebo Control for the Treatment
of In-Stent Restenosis. Circulation, 106:9, 1090-1096, 2002.
29. Morino, Y., Kaneda, H., Fox, T., Takagi, A., Hassan, H.M., Honda, Y., Bonan, R., Crocker, I., Lansky,
A.J., Laskey, W.K., Suntharalingam, M., Bonneau, H.N., Yock, P.G., Fitzgerald, P.J. Delivered
Dose and Vascular Response Following Beta Radiation for In-Stent Restenosis: Retrospective
Dosimetry and Volumetric Intravascular Ultrasound Analysis. Circulation, 106:18, 2334-2339, 2002.
30. Li, X.A., Chilbani, O., Greenwald, B., Suntharalingam, M. Radiotherapy Dose Pertubation of Metallic
Esophageal Stents. International Journal of Radiation Oncology, Biology and Physics, 54:4, 12761285, 2002.
31. Mao, Y.S., Suntharalingam, M., Krasna, M.J. Management of Late Distant Metastases After
Trimodality Therapy for Esophageal Cancer. The Annals of Thoracic Surgery, 76:5, 1742-1743,
2003.
32. Suntharalingam, M., Laskey, W.K., Tan, J., Kuntz, R., Bonan, R. Vascular Brachytherapy Using A
Beta Emitter in Diabetic Patients with In-Stent Restenosis: Angiographic and Clinical Outcomes.
International Journal of Radiation Oncology, Biology and Physics, 57:2, 536-542, October 2003.
33. Suntharalingam, M., Moughan, J., Cola, L.R., Krasna, M.J., Kachnic, L., Haller, D.G., Willet, C.G.,
John, M.J., Minksy, B.D., Owens, J.B. The National Practice for Patients Receiving Radiation
Therapy for Carcinoma of the Esophagus: Results of the 1996-1999 Patterns of Care Study.
International Journal of Radiation Oncology, Biology and Physics, 56:4, 981-987, 2003.
34. Timmerman, R., Papiez, L., Suntharalingam, M. Extracranial Stereotactic Radiation Delivery:
Expansion of Technology beyond the Brain. Technology in Cancer Research and Treatment, 2:2,
153-160, 2003.
35. Edelman, J.J., Suntharalingam, M., Krasna, J.J. The Management of the Patient Undergoing
Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. Current Treatment
Options in Oncology, Vol. 4(1), pp 45-53, February 2003.
36. Flannery, T.A., Suntharalingam, M., Kwok, Y., Koffman, B.H., Amin, P.A., Chin, L.S., Nichol, B.,
Fowler, B., Young, B., Regine, W.F. Gamma Knife Stereotactic Radiosurgery for Synchronous
Versus Metachronous Solitary Brain Metastases from Non-Small Cell Lung Cancer. Lung Cancer,
32:3, 327-333, December 2003.
37. Rhee, J.G., Li, D., Guo, M., O’Malley Jr., B.W, Suntharalingam, M. Combination Radiation and
Adenovirus Mediated p16 (INK4A) in a Murine Model for Head and Neck Cancer. Journal of ORL,
65:3, 144-154, June 2003.
12
PUBLICATIONS – JOURNAL ARTICLES – Continued
38. O’Malley Jr, B.W., Li, D., Carney, J., Rhee, J., Suntharalingam, M. Molecular Disruption of the
MRN(95) Complex Induces Radiation Sensitivity in Head and Neck Cancer. Laryngoscope, 13:9,
1588-1594, September 2003.
39. Brady, D., Yu, S.Z., Koprowski, H., Rhee, J., Kuman, S., Pericle, F., Suntharalingam, M., Van Echo,
D.A., Li, D., O’Malley Jr., B.W. Combination Non-Viral Interleukin-2 Gene Therapy and External
Beam Radiation Therapy for Head and Neck Cancer. Archives of Otolaryngol Head and Neck, 129:6,
618-622, June 2003.
40. Suntharalingam, M. The Role of Concurrent Chemotherapy and Radiation in the Management of
Patients with Squamous Cell Carcinomas of the Head and Neck. Seminars in Oncology, 30:4, Suppl
(9), 37-45, August 2003.
41. Suntharalingam, M., Jaboin, J, Taylor, R., Wolf, J., Bangalore, M., Van Echo, D., Ord, R. The
Evaluation of Amifostine for Mucosal Protection in Patients with Advanced Lco-Regional Squamous
Cell Carcinomas of the Head and Neck (SCCHN) Treated with Concurrent Weekly Carboplatin,
Paclitaxel and Daily Radiotherapy (RT). Seminars in Oncology, 31 (6 Suppl 18), 2-7, December 2004
42. Sonett, J.R., Suntharalingam, M., Edelman, M.J., Gamliel, Z., Doyle, A., Hausner, P., Dickerson, A.,
Krasna, M.J. Pulmonary Resection Following Neoadjuvant High Dose Curative Intent Radiotherapy
(>59Gy) and Concurrent Chemotherapy. The Annals of Thoracic Surgery, 78:4, 1200-1205, October
2004.
43. Patel, A.B., Edelman, M.J., Kwok, Y., Krasna, M.J., Suntharalingam, M. Predictors of Acute
Esophagitis in Patients with Non-Small Cell Lung Carcinoma Treated with Concurrent Chemotherapy
and Hyperfractionated Radiation Therapy Followed by Surgery. The International Journal of
Radiation Oncology, Biology and Physics, (60) 4:1106-1112, 2004.
44. Silber, S., Popma, J.J., Suntharalingam, M., Lansky, A.J., Heuser, R.R., Spieser, B., Teirstein, P.S.,
Bass, T., O’Neill, W., Lasala, J., Reisman, M., Sharma, S.K., Kuntz, R.E., Bonan, R. Two-Year
Clinical Follow-Up of 90 Sr/90 Y Beta Radiation Versus Placebo Control for the Treatment of In-Stent
Restenosis. The American Heart Journal, 149: 689-694, 2005.
45. Yovino, S., Kwok, Y., Krasna, MJ., Bangalore, M., Suntharalingam, M., An association between
preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients
treated with surgery alone. Int J Radiat Oncol Biol Phys, 62(5), 1438-43, August 2005.
46. Kwong, K., Cooper, L., Edelman, M.J., Gamliel, Z., Suntharalingam, M., Burrows, W., Hausner, P.,
Doyle, L.A., Krasna, M.J. High-Dose Radiation in tri-Modality Treatment of Pancoast tumors Results
in High Pathologic Complete Response Rates and Excellent Long-term Survival. The Journal of
Thoracic and Cardiovascular Surgery, 29 (6) 1250-7, June 2005.
47. Suntharalingam, M., Moughan, J., Coia, L.R., Krasna, M.J., Kachnic, L., Haller, D.G., Willett, C.G.,
John, M.J., Minsky, B.D., Owen, J. Outcome Results of the 1996-1999 Patterns of Care Survey of
the National Practice for Patients Receiving Radiation Therapy for Carcinoma of the Esophagus. J
of Clinical Oncology, 20, 10:2325-2331, 2005.
48. Li, XA, O’Neill, M., Suntharalingam, M. Improving patient-specific dosimetry for intravascular
brachytherapy. Brachytherapy, 4: 291-97, 2005.
49. Hamilton, JP, Sato F, Greenwald BD, Suntharalingam, M., Krasna, MJ, Edelman, MJ, Doyle, A.,
Berki, AT, Mori, Y., Kan, T., Mantzur, C., Paun, B., Wang, S., Ito, T., Jin, Z., Meltzer, SJ. Promoter
methylation and response to chemotherapy and radiation in esophageal cancer. Clin. Gastroenterol
Hepatol, Epub, May 2006, Vol 4(6); page 701-708, June 2006.
13
PUBLICATIONS – JOURNAL ARTICLES – Continued
50. Bangalore, M., Matthews, S., Suntharalingam, M. Recent Advances in Radiation Therapy for Head
and Neck Cancer. Journal for Otorhinolaryngology, November 2007.
51. Balcer-Kubiczek, E., Attarpour, M., Jiang, J., Kennedy, AS, Suntharalingam, M. Cytotoxicity of
Docetaxel (Taxotere) used as a Single Agent and in Combination with Radiation in Human Gastric,
Cervical and Pancreatic Cancer Cells. Chemotherapy, 52:231-240, 2006.
52. Suntharalingam, M. Definitive chemoradiation in the management of locally advanced esophageal
cancer. Seminars in Oncology, 17(1), 22-28, January 2007.
53. D’Souza, WD., Nazareth, DP., Zhang, B., DeYoung, C., Suntharalingam, M., Kwok, Y., Yu, CX.,
Regine, WF. The use of gated and 4d CT imaging in planning for stereotactic body radiation therapy.
Med Dosim., Vol. 32(2), pp 92-101, June 2007.
54. Safran, H., Suntharalingam, M., Dipetrillo, T., Ng, T., Doyle, LA, Krasna, MJ, Plette, A., Evans, D.,
Wanebo, H., Akerman, P., Spector, J., Kennedy, N., Kennedy, T. Cetuximab with Concurrent
Chemoradiation for Esophagogastric Cancer: Assessment of Toxicity. Int J Radiat Oncol Phys.,
November 2007.
55. Rhee, JG, LI, D., Suntharalingam, M., Guo, C., O’Malley, BW, Carney, JP. Radiosensitization of
head/neck squamous cell carcinoma by adenovirus-mediated expression of the Nbs 1 protein. Int J
Radiation Oncol Biol Phys, 67(1), 273-78, January 2007.
56. Machtay, M., Pajak, TF, Suntharalingam, M., Shenouda, G., Hershock, D., Stripp, DC, Cmelak, AJ.,
Schulsinger, A., Fu, KK. Radiotherapy with or without Erythropoietin for Anemic Patients with Head
and Neck Cancer: A Randomized Trial of the Radiation therapy Oncology Group (RTOG 99-03). Int
J Radiat Oncol Biol Phys, 69(4) 1008-1017, October 2007.
57. D’Souza, WD, Nazareth, DP, Zhang, B., DeYoung, C., Suntharalingam, M. Kwok, Y., Yu, CX,
Regine, WF. The Use of Gated and 4D CT Imaging in Planning for Stereotactic Body Radiation
Therapy. Med Dosim, 32(2), 92-101, May 2007.
58. Yovino, S., Settle, K., Taylor, R., Wolf, J., Kwok, Y., Cullen, K., Ord, R., Zimrin, A., Strome, S.,
Suntharalingam, M. Can Adjuvant Neck Dissection Be Deferred in Patients with Squamous Cell
Carcinoma of the Head and Neck Who Obtain A Complete Response to Definitive
Chemoradiotherapy. Int. J. Radiation Oncology Biol Phys., Vol. 69(3), pp S15., 2008
59. Safran, H., Suntharalingam, M., DiPetrillo, T., Ng, T., Doyle, LA, Krasna, M., Plette, A., Evans, D.,
Wanebo, H., Akerman, P., Spector, J., Kennedy, N., Kennedy, T. Cetuximab with Concurrent
Chemoradiation for Esophagogastric Cancer: Assessment and Toxicity. Int. J. Radiation Oncology
Biol Phys., Vol. 70, No.2, pp 391-395, 2008.
60. Corn, BW., Wexler, ID., Suntharalingam, M., Inbar, M., Curran, WJ., Jr., Radiation Therapy
Oncology Group. Globalization of the Radiation Therapy Oncology Group: Implementation of a
model for service expansion and public health improvement. J. Clin Oncol, Vol., 26(7), pp 11601166, March 1, 2008.
61. Wu, J., Li, H., Shekhar, R., Suntharalingam, M., D’Souza, W. An evaluation of planning techniques
for stereotactic body radiation therapy in lung tumors. Epub. March 2008, Radiother Oncol, Vol 87(1),
pp 35-43, April 2008.
62. Flannery, T.W., Suntharalingam, M., Regine, W.F., Chin, L.S., Krasna, M.J., Shehata, M.K.,
Edelman, M.J., Kremer, M., Patchell, R.A., Kwok, Y. Long-Term Survival in Patients with
Synchronous, Solitary Brain Metastasis from Non-Small Cell Lung Cancer Treated with Radiosurgery.
Int. J. Radiation Oncology Biol Phys., Vol 72(1), pp. 19-23, September 2008.
14
PUBLICATIONS – JOURNAL ARTICLES – Continued
63. Edelman, MJ., Suntharalingam, M., Burrows, W., Kwong, KF., Mitra, N., Gamliel, Z., Riley, M.,
Cooper, LB., Kennedy, NL, Buskirk, S., Hausner, P., Doyla, LA, Krasna, MJ. Phase I/II Trial of
hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Ann
Thoracic Surg., Vol. 86(3), pp 903-910. September 2008.
64. Edelman, MJ, Burrows, W, Krasna, MJ, Suntharalingam, M. Phase I Trial of Carboplatin/Paclitaxel/
Bortezomib and Concurrent Radiotherapy followed by Surgical Resection in Stage III Non-Small Cell
Lung Cancer. J of Thoracic Onc. January 2009.
65. Saito, K., Khan, K., Yu, SZ, Ronson, S., Rhee, J., Li, G., Van Echo, D. Suntharalingam, M.,
O’Malley, BW, Jr., Li, D. The Predictive and Therapeutic Value of Thymidine Phosphorylase and
Dihydropyrimidine Dehydrogenase in Capecitabine (Xeloda)-based Chemotherapy for Head and
Neck Cancer. Laryngoscope, Vol., 119(1), pp 82-88, January 2009.
66. Patel, S., Macdonald, OK, Suntharalingam, M. Evaluation of the Use of Prophylactic Cranial
Irradiation in Small Cell Lung Cancer. Cancer, Vol. 115 (4), pp 842-850, February 2009.
67. Neuner, G., Patel, A., Suntharalingam, M. Chemoradiotherapy for Esophageal Cancer.
Gastrointestinal Cancer Research, March/April 2009.
68. Settle, K., Taylor, R., Wolf, J., Young, K. Cullen, K., Carter, K., Ord, R., Zimrin, A., Strome, S.,
Suntharalingam, M. Race Impacts Outcome in Stage III/IV Squamous Cell Carcinomas of the Head
and Neck Following Concurrent Chemoradiation Therapy. Cancer, Vol. 115 (8), pp. 1744-1752, April
15, 2009.
69. Kim, C., Monjazeb, AM, Suntharalingam, M., Giesinger, KR, Blackstock, AW. Preoperative Versus
Postoperative Chemoradiotherapy in the Trimodality Management of Esophageal Cancer. Clinical
Advances In Hematology & Oncology, Vol. 7 (5) pp. 327-324, May 2009.
70. Yovino, S., Settle, K., Taylor, R., Wolf, J., Kwok, Y., Cullen, K., Ord, R., Zimrin, A., Strome, S.,
Suntharalingam, M. Phase I Trial of Carbonplating/Paclitaxel/Bortezomib and Concurrent
Radiotherapy followed by Surgical Resection in Stage III Non-Small Cell Lung Cancer. Head & Neck,
May 2009.
71. Cheng, S., Iannettoni, M., Koshy, M., Suntharalingam, M., Urba, S. Squamous Cell Carcinoma of
the Esophagus: Treat With How Many Modalities? Seminars in Oncology, Vol. 36 (6) pp 493-497.
72. Jianzhou, W., Peng, L., Raj, S., Huiling, L., Suntharalingam, M, D’Souza, W. Do Tumors in the lung
deform during normal respiration? An image registration investigation. International Journal of
Radiation Oncology Biology Physics, Vol. 75(1); pp 268-275. September, 2009.
73. Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, Strome SE, Haddad
RI, Patel SS, Campbell EV, Sarlis N, Lorch J, Cullen KJ. Racial Survival Disparity in Head and Neck
Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal
Cancer Patients. Cancer Pre Res, Vol. 2(9); 776-81, Sep 2009.
74. Jin, Z., Yi, BY, Lasio, G., Suntharalingam, M, Yu, C. Tomographic image via background
subtraction using an x-ray projection image and a priori computed tomography. Medical Physics, Vol.
36(10); 4433-4439, Nov. 2009.
75. D’Souza, WD, Malinowski, KT, Van Liew, S, D’Souza, G, Asbury, K., Suntharalingam, M., Regine,
WF. Investigation of Motion Sickness and Inertial Stability on a Moving Couch for Intra-Fraction
Motion Compensation. Acta Oncologica, Vol. 48(8), pp 1198-1203, November, 2009.
15
PUBLICATIONS – JOURNAL ARTICLES – Continued
76. Peng HQ, Halsey K, Sun CC, Manucha V., Nugent S., Rodgers WH, Suntharalingam, M. Greenwald
BD. Clinical Utility of Postchemoradiation Endoscopic Brush Cytology and Biopsy in Predicting
Residual Esophageal adenocarcinoma. Cancer Cytopathol, Vol. 117(6); 463-72. December 25,
2009.
77. Lim, DH, Yi, BY, Mirmiran, A, Dhople, A, Suntharalingam, M. Optimal Beam Arrangement for
Stereotactic Body Radiation Therapy Delivery in Lung Tumors. Acta Oncologica, Vol. 49, pp 219224, 2010.
78. Yovino S, Settle K, Taylor R, Wolf J, Kwok Y, Cullen KJ, Ord R, Zimrin A, Strome S, Suntharalingam
M. Patterns of Failure Among Patients with Squamous Cell Carcinoma of the Head and Neck who
obtain a complete response to chemoradiotherapy. Head & Neck, Vol. 32(1); pp 46-52, January
2010.
79. Krasna MJ, Gamliel Z, Burrows WM, Sonett JR, Kwong KF, Edelman MJ, Hausner PF, Doyle LA,
DeYoung C, Suntharalingam, M. Pneumonectomy for Lung Cancer After Preoperative Concurrent
Chemotherapy and High-dose Radiation. Ann Thorac Surg, Vol. 89(1); 200-206, January 2010.
80. Koshy M, Goloubeva O, Suntharalingam, M. Impact of Neoadjuvant Radiation on Survival in Stage
III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys, Jun, 2010.
81. Koshy M, Greenwald BD, Hausner P, Krasna MJ, Horiba N, Battafarano RJ, Burrows W,
Suntharalingam M. Outcomes After Trimodality Therapy for Esophageal Cancer: The Impact of
Histology on Failure Patterns. Am J Clin Oncol, Aug 3, 2010.
82. Edelman MJ, Burrows W, Krasna MJ, Bedor M, Smith R, Suntharalingam M. Phase I Trial of
carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage
III non-small cell lung cancer. Lung Cancer, Vol. 68, pgs 84-88, 2010.
83. Rutter CE, Yovino S, Taylor R, Wolf J, Cullen KJ, Ord R, Athas M, Zimrin A, Strome S,
Suntharalingam M. Impact of Early Percutaneous Endoscopic Gastrostomy Tube Placement on
Nutritional Status and Hospitalization in Patients with Head and Neck Cancer Receiving Definitive
Chemoradiation Therapy. Head & Neck, Dec 15, 2010.
84. Dipetrillo T, Suntharalingam M, Ng T, Fontaine J, Horiba N, Oldenburg N, Perez K, Birnbaum A,
Battafarno R, Burrows W, Safran H. Neoadjuvant Paclitaxel Poliglumex, Cisplatin, and Radiation for
Esophageal Cancer: A Phase 2 Trial. Am J Clin Oncol. Feb 3, 2011.
85. Strongin A, Yovino S, Taylor R, Wolf J, Cullen K, Zimrin A, Strome S, Regine W, Suntharalingam M.
Primary Tumor Volume is an Important Predictor of Clinical Outcomes Among Patients with Locally
Advanced Squamous Cell Cancer of the Head and Neck Treated with Definitive Chemoradiotherapy.
Int J Radiat Oncol Biol Phys. May 5, 2011.
86. Patel S, Macdonald OK, Nagda S, Bittner N, Suntharalingam, M. Evaluation of the Role of
Radiation Therapy in the Management of Malignant Thymoma. Int J Radiat Oncol Biol Phys. May
17, 2011, [Epub ahead of print].
87. Suntharalingam M, Kwok J, Goloubeva O, Parekh A, Taylor R, Wolf J, Zimrin A, Strome S, Ord R,
Cullen KJ. Phase II Study Evaluating the Addition of Cextuximab to the Concurrent Delivery of
Weekly Carboplatin, Paclitaxel, and Daily Radiotherapy for Patients with Locally Advanced
Squamous Cell Carcinomas of the Head and Neck. Int J Radiat Oncol Biol Phys. May 19, 2011
[Epub ahead of print].
16
PUBLICATIONS – JOURNAL ARTICLES – Continued
88. Mahmood U, Koshy M, Goloubeva O, Suntharalingam M. Adjuvant Radiation Therapy for HighGrade and/or Locally Advanced Major Salivary Gland Tumors. Arch Otolaryngol Head Neck Surg,
137(10); 1025-1030. October, 2011.
89. Tan S, Kligerman S, Chen W, Lu M, Kim G, Feigenberg SJ, D’Souza WD, Suntharalingam, M.
Spatial-Temporal FDG-PET Features for Predicting Pathologic Response of Esophageal Cancer to
Neoadjuvant Chemoradiotherapy. Int J Radiat Oncol Biol Phys, 2012.
90. Suntharalingam, M, Paulus R, Edelman MJ, Krasna M, Burrows W, Gore E, Wilson LD, Choy H.
Radiation Therapy Oncology Group Protocol 02-29: A Phase II Trial of Neoadjuvant Therapy with
Concurrent chemotherapy Full-Dose Radiation Therapy Followed by Surgical Resection
Consolidative Therapy for Locally Advanced Non-small Cell Carcinoma of the Lung. Int J Radiat
Oncol Biol Phys, Vol. 84, 2, pgs 456-463, October, 2012.
91. Vosken CJ, Sewell D, Hertzano R, DeSanto J, Rollins S, Lee M, Taylor R, Wolf J, Suntharalingam
M, Gastman B, Papadimitriou JC, Lu C, Tan M, Morales R, Cullen K, Celis E, Mann D, Strome SE.
Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck
carcinoma. Head Neck, Vol. 34(12), pp 1734-1746, December, 2012.
92. Howell, DD, James, JL, Hartsell, WF, Suntharalingam, M, Machtay, M, Suh, JH, Demas, WF,
Sandler, HM, Kachnic LA, Berk, LB. Single-Fraction Radiotherapy Versus Multifraction Radiotherapy
for Palliation of Painful Vertebral Bone Metastases – Equivalent efficacy, Less Toxicity, More
Convenient. Cancer, Vol 119, pgs 888-896, February, 2013.
93. Beutel G, Perthel R, Suntharalingam M, Bode-Boger SM, Martens-Lobenhoffer J, Kielstein JT,
Kielstein H. Effect of Chronic Elevated Asymmetric Dimethylarginine (ADMA) levels on
Granulopoiesis. Ann Hematol, Vol. 92(4) 505-508, April 2013.
94. Zhang H, Tan S, Chen W, Kligerman, S, Kim, G, D’Souza, WD, Suntharalingam, M. Modeling
Pathologic Response of Esophageal Cancer to Chemoradiation Therapy Using Spatial-Temporal 18FFDG PET Features, Clinical Parameters, and Demographics. Int J Radiat Oncol Biol Phys, Sept.
2013.
95. Zhang H, Tan S, Chen W, Kligerman S, Kim G, D’Souza WD, Suntharalingam M, Lu W. Modeling
Pathologic Response of Esophageal Cancer to Chemoradiation Therapy Using Spatial-Temporal (18)
F-FDG PET Features, Clinical Parameters, and Demographics. Int J Radiat Oncol Biol Physics. Vol.
88(1) 195-203, Jan, 2014.
96. Kim GJ, Koshy M, Hanlon AL, Horiba MN, Edelman MJ, Burrows, WM, Battafarano RJ,
Suntharalingam M. The Benefit of Chemotherapy in Esophageal Cancer Patients with Residual
Disease After Trimodality Therapy. Am J Clin Oncol. Jan, 2014 [Epub ahead of print]
BOOK CHAPTERS
1. Salazar, O.M., Suntharalingam, M. Palliative Radiation for Widespread Pulmonary Disease in
Medical Radiology in Kagan R., Steckel, R., (eds), Practical Approaches to Cancer Invasion and
Metastasis. Springer Verlag, 1994.
2. Suntharalingam, M. Principles and Complications of Radiation Therapy in Ord, R.A and Blanchart,
R.H. (eds), Oral Cancer: The Dentist’s Role in Diagnosis, Management, Rehabilitation and
Prevention. Quintessence Publishing, 1999.
17
BOOK CHAPTERS - Continued
3. Paz, I.B., Suntharalingam, M., Leichman, L. Esophageal Cancer in Pazdur, R., Coia, L.R., Hoskins,
W.J., Wagman, L.D. (eds), Cancer Management: A Multidisciplinary Approach. Medical, Surgical
and Radiation Oncology, 5th Edition, PRR Inc, 2001.
4. Paz, I.B., Suntharalingam, M., Hwang, J.J., Marshall, J.L., Leichman, L. Esophageal Cancer in
Pazdur, R., Coia, L.R., Hoskins, W.J., Wagman, L.D. (eds), Cancer Management: A Multidisciplinary
Approach. Medical, Surgical and Radiation Oncology, 5th Edition, PRR Inc., 2002.
5. Moore-Higgins, G.J., Strohl, R.A., Suntharalingam, M. Lung Cancer, in Bruner, D.W., MooreHiggins, G.J., Haas, M. (eds), Outcomes in Radiation Therapy. Multidisciplinary Management, 2001.
6. Paz, I.B., Suntharalingam, M., Hwang, J.J., Marshall, J.L., Leichman, L. Esophageal Cancer in
Pazdur, R., Coia, L.R., Hoskins, W.J., Wagman, L.D. (eds), Cancer Management: A Multidisciplinary
Approach. Medical, Surgical and Radiation Oncology, 8th Edition, PRR Inc., 2003.
7. Paz, I.B., Hwang, J.J., Marshall, J.L., Leichman, L., Suntharalingam, M. Esophageal Cancer in
Pazdur, R., Coia, L.R., Hoskins, W.J., Wagman, L.D. (eds), Cancer Management: A Multidisciplinary
Approach. Medical, Surgical and Radiation Oncology, 8th Edition, PRR Inc, 2004.
8. Suntharalingam, M, Settle, K., Cullen, K. Perspective on Fractionated Radiation and Chemotherapy
for Head and Neck Tumors, Chin, L., Regine, W.F. (eds) in Principles and Practice of Stereotactic
Radiosurgery, 1st edition, Springer, 2005.
9. Patel, A.B., Suntharalingam, M. Definitive Radiochemotherapy in Esophageal Tumors: Principles
and Practice. Jobe BA, Thomas CR, Hunter JG, Tran N, Editors. Demos Medical Publishing, March
2009.
POSTER PRESENTATIONS
1. Suntharalingam, M., Rhee, J., Eddy, H., Salazar, O.M. Reoxygenation Kinetics in RIF-1 Multi-Cell
Spheroids Characterized by the Changes in Cytotoxicity of X-Rays and SR-4233, A Hypoxic Cell
Toxin. Presented at the American Society for Therapeutic Radiology and Oncology Annual Meeting.
San Francisco, CA, October, 1994.
2. Suntharalingam, M., Ampey, L.L. A Radiobiologic Evaluation of Overall Treatment Time in Patients
with Early Stage Glottic Carcinoma. Presented at The American Radium Society Annual Meeting.
Paris, France, April 29 – May 3, 1995.
3. Moon, S.D.M., Suntharalingam, M., Liu, J, Rhee, J.G. Reoxygenation Patterns of RIF-1 Multi-Cell
Spheroids Determined by Halo and Halo-Comet Assays Following SR-4233 Exposures. Presented at
the Radiation Research Society Meeting. Chicago, IL, April, 1996.
4. Rhee, J.G., Lee, K.H., Liu, J., Um, K.I., Vines, E., Suntharalingam, M. A Constant Level of HSP70
During a Transitional Period from a Heat-Sensitive to a Heat-Resistant State Following Dispersion of
RIF-1 Spheroids. Presented at the North American Hyperthermia Society Meeting. Providence, RI,
May, 1997.
5. Park, S., Suntharalingam, M., Gray, W., Saraf, W., Elias, G. Comparison of Condensed Modality
Treatment with Chemotherapy and Radiation Versus Radiation Alone on Patients with
Nasopharyngeal Cancer: A Retrospective Review. Presented at the 1997 Annual Meeting of the
Society of Head and Neck Surgeons. Cancun, Mexico, April 10-12, 1997.
6. Rhee, J.G., Suntharalingam, M., Mansfield, C.M. Localization of Tirapazamine Induced DNA
Damage in RIF-1 Multi-Cell Spheroids; in Situ Alkaline Comet Assay (ISACA). Presented at the
Radiation Research Society Meeting. Louisville, KY, May 1998.
18
POSTER PRESENTATIONS - Continued
7. Suntharalingam, M., Conley, B.A., Van Echo, D.A., Jacobs, M.C., Levy, S.G., Li, B., Ord, R.A., Gray,
W.C., Aisner, J.A. Evaluation of Response and Survival in Unresectable SCCHN Treated with
Chemoradiation on Three Consecutive Institutional Trials. Presented at the First International
Chicago Symposium on Malignancies of the Chest, Head and Neck. October 1-2, 1999.
8. Haddad, R.I., Suntharalingam, M., Chen,T., Levy, S., Van Echo, D.E. Pre-Treatment Hemoglobin is
Associated with Response to Chemoradiation (CRT) in Patients with Advanced Unresectable
Squamous Cell Carcinoma of the Head and Neck. Presented at the American Society of Clinical
Oncology Annual Meeting. New Orleans, LA, May 20-23, 2000.
9. Fowler, B.Z., Suntharalingam, M., Koffman, B.H., Nichols, B., Chin, L., Amin, P.A., Young, A.B.,
Regine, W.F. Gamma Knife Stereotactic Radiosurgery for Synchronous Versus Metachronous
Solitary Brain Metastases from Non-Small Cell Lung Cancer. Presented at The American Society of
Therapeutic Radiology and Oncology 42nd Annual Meeting. Boston, MA, October 22-26, 2000.
10. Suntharalingam, M., DeYoung, C.M., Edelman, M.J., Greenwald, B., Duckham, E., Krasna, M.J.
Concomitant Boost RT as Part of an Induction Regimen Followed by Surgery and Adjuvant Docetaxel
for Locally Advanced Esophageal Cancer. Presented at the 38th Annual Meeting of the American
Society of Clinical Oncology. Orlando, FL, May 18-21, 2002.
11. Sullivan, PH, Taylor, R, Ord R, Wolf, J, VanEcho D, Kwok Y, Suntharalingam, M. Long-Term
Survival and Functional Quality of Life Assessments in Patients with Locally Advanced Unresectable
Squamous Cell Carcinomas of the Head and Neck Treated with Concurrent Chemoradiation,
presented at the 45th Annual Meeting of the American Society of Therapeutic Radiology and
Oncology, Atlanta, GA, Oct. 3-7, 2004.
12. Yovino S, Kwok Y, Krasna MJ, Bangalore M, Suntharalingam, M. Preoperative Anemia Decreases
Survival in Patients with Stage I and II Non-Small Cell Lung Cancer. Presented at the 46th Annual
Meeting of the American Society of Therapeutic Radiology and Oncology, Atlanta, GA, October,2004.
13. Suntharalingam, M., Wolf, J., Taylor, R., Jaboin, J., Bangalore, M., Ord, R., Cullen, K. The
Evaluation of Amifostine for Mucosal Protection in Advanced Loco-Regional Squamous Cell
Carcinomas of the Head and Neck (SCCHN) Treatment with Concurrent Weekly Carboplatin,
Paclitaxel, and Daily Radiotherapy (RT). Presented at the American Society of Therapeutic
Radiology and Oncology (ASTRO) 47th Annual Meeting. Denver, CO, October 16-20, 2005.
14. Suntharalingam, M., Paulus, R., Edelman, MJ., Krasna, M., Burrows, W., Gore, E., Yom, SS., Choy,
H. A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and High Dose
Radiotherapy Followed by Surgical Resection and Consolidative Therapy for LA NSCLC. Presented
at ASCO Annual Meeting. Chicago, IL., June 2010.
NATIONAL PRESENTATIONS – INVITED SPEAKER
1. Radiation Modifiers: From Discovery to Reality: Suntharalingam, M., Salazar, O.M. Presented at the
8th Bicenntial Meeting of Circulo De Radioterapeutas Ibero Latino Americans (CRILA). San Juan,
Puerto Rico, May 4-8, 1992.
2. Technical Considerations of Ultrasound and Template Guided I125 Implantation for Early Stage
Prostate Cancer. Presented at the Mid-Atlantic Society for Radiation Oncology Meeting. Richmond,
VA, September 23, 1992.
19
NATIONAL PRESENTATIONS – INVITED SPEAKER – Continued
3. Organ Preservation in Advanced Larynx Cancer: A Radiation Oncologist’s Perspective. Presented at
the Southern Medical Association Annual Meeting. Baltimore, MD, November 22, 1996.
4. Staging and Combined Modality Treatment for Esophageal Cancer Radiation Oncology with TriModality Treatment Panel Discussion. Presented at the Multidisciplinary Treatment of Solid Tumors
Conference, Baltimore, MD, September 19-20, 1997.
5. Multidisciplinary Treatment of Solid Tumors Conference. Baltimore, MD, September 19-20, 1997.
6. The University of Maryland Experience with the Beta Cath Trial. Presented at the Novosote
European Investigators Meeting. Brussels, Belgium, June 1998.
7. The Use of Radiation Therapy to Prevent Coronary Artery Restenosis. Presented at the Radiation
Oncology Ground Rounds, Rush Presbyterian Hospital. Chicago, IL, July 1998.
8. Radiation Therapy with Concurrent Weekly Carboplatin and Paclitaxel in Advanced Stage
Unresectable Squamous Cell Carcinomas of the Head and Neck. Presented at the Fox Chase
Cancer Center Investigator Workshop. Lanai, HI, March 11-15, 2000.
9. Clinical Implementation of Intensity-Modulated Arc Therapy. Presented at the International
Symposium on Intensity-Modulated Radiation Therapy. Jefferson Medical College, Philadelphia, PA,
March 17-18, 2000.
10. The Role of Radiation in the Prevention of Vascular Restenosis. Presented at the Device Workshop
at the Society of Cardiac Angiography and Interventions Meeting. Charleston, SC, May 4, 2000.
11. The Role of Vascular Brachytherapy in the Prevention of Coronary Artery Restenosis. Presented at
the American College of Medical Physicist (ACMP) Annual Meeting. Vancouver, Canada, May 18,
2000.
12. Combining Radiation and Chemotherapy in the Treatment of Head and Neck Carcinomas. Presented
at Oncology Ground Rounds, University of Louisville. Louisville, KY, August 17, 2000.
13. The Role of Radiation in the Prevention of Coronary Artery Restenosis. Presented to the Department
of Radiation Oncology and Combining Radiation and Chemotherapy in the Treatment of Head and
Neck Carcinomas. Presented at Oncology Ground Rounds as Visiting Professor, Department of
Radiation Medicine, University of Kentucky. Lexington, KY, August 18, 2000.
14. Advances in the Treatment of Head and Neck Cancer. Presented at Cancer Center Ground Rounds,
Divine Providence Hospital. Williamsport, PA, August 29, 2000.
15. Innovations in the Use of Radiotherapy for Head and Neck Cancer. Presented at the 5 th Annual
National VA Oncology Symposium. Alexandria, VA, October 5, 2000.
16. Multi-Modality Treatment for Early Stage Head and Neck Carcinomas. Presented at the Bristol-Myers
Squibb Oncology Physician Speakers Training Program. Chicago, IL, October 5-7, 2000.
17. Implementation of a Vascular Brachytherapy Program. Presented at the Transcatheter Therapeutics
National Meeting. Washington, DC, October 19, 2000.
18. IMRT Delivery Approaches and Clinical Experience with IMAT (Intensity Modulated Radiation
Therapy). Presented at the Elekta Symposium on Advanced Clinical Solutions in Conformal
Radiotherapy (IMRT) and Gamma Knife Surgery, American Society of Therapeutic Radiology and
Oncology 42nd Annual Meeting. Boston, MA, October 21, 2000.
20
NATIONAL PRESENTATIONS – INVITED SPEAKER – Continued
19. Moderator - Scientific Session on Coronary Vascular Radiation at the 42 nd Annual Meeting of the
American Society for Therapeutic Radiology and Oncology. Boston, MA, October, 30, 2000.
20. Clinical Applications of Intensity-Modulated Radiation Therapy. Presented at the Gulf Coast
Oncology Center. Panama City, FL, November 13, 2001.
21. Combined Modality Management of Head and Neck Cancer. Presented at Educational Symposium
at the American Society of Therapeutic Radiation and Oncology Annual Meeting. San Francisco, CA,
November 4, 2001.
22. Moderator - Endovascular Brachytherapy Scientific Session at the 43rd Annual Meeting of the
Association for Therapeutic Radiology and Oncology. San Francisco, CA, November 7, 2001.
23. The Role of Endovascular Brachytherapy in the Management of In-Stent Restenosis. Presented at
the 2001 Scientific Symposium of the Delaware Valley Chapter of the American Association of
Physicists in Medicine Meeting, Jefferson Medical College. Philadelphia, PA, December 7, 2001.
24. Co-Moderator - The Annual Simon Kramer Institute Symposium for the Development of a New
Staging System for Esophageal Cancer. New Philadelphia, PA, August 25, 2001.
25. The Role of Staging in the Treatment of Esophageal Cancer with Pre-Operative Chemotherapy and
Radiation. Presented at the Annual Simon Kramer Institute Symposium for the Development of a
New Staging System for Esophageal Cancer. New Philadelphia, PA, August 25, 2001.
26. The University of Maryland Experience with Chemoradiation in Locally Advanced Head and Neck
Cancer. Presented at the Fox Chase Cancer Center Investigator Workshop. Kohala, HI, March 2327, 2002.
27. Current Trends in the Management of Locally Advanced Carcinomas of the Head and Neck.
Presented at the Carolina Regional Tumor Conference. Raleigh, NC, June 3, 2002.
28. Current Trends in the Management of Locally Advanced Carcinomas of the Head and Neck.
Presented at Virginia Regional Cancer Meeting. Virginia Beach, VA, June 4, 2002.
29. The Role of Functional Imaging in Radiation Oncology Research Strategies. Presented at Elekta
Users Meeting. Nassau, Bahamas, May 31, 2003.
30. Clinical Implementation of an Intensity-Modulated Radiation Therapy Program. Presented at the
Annual Meeting of the Atlanta Oncology Associates. Atlanta, GA, August 23, 2003.
31. The Role of Combined Modality Therapy for Locally Advanced Squamous Cell Carcinomas of the
Head and Neck. Presented at Grand Rounds of the Cancer Center at Wake Forest University
Medical School. October 3, 2003.
32. Combined Modality Management of Head and Neck Cancer. Presented at Educational Symposium
at the American Society of Therapeutic Radiation and Oncology Annual Meeting. Salt Lake City, UT,
October 19, 2003.
33. Recent Innovations in Radiation Oncology and Paradigm Changes. Presented at the Washington
D.C. Veterans Administration Hospital Medical Grand Rounds. Washington, DC, November 5, 2003.
34. Outcome Results of the 1996-1999 Patterns of Care Survey of the National Practice for Patients
Receiving Radiation Therapy for Carcinoma of the Esophagus. Presented at the 89 th Annual Meeting
of Radiological Society of North America Special Focus Session – ASTRO Invited Papers. December
1, 2003.
21
NATIONAL PRESENTATIONS – INVITED SPEAKER – Continued
35. Clinical Applications of Intensity-Modulated Radiation Therapy. Presented at the University of
Colorado Radiation Oncology Grand Rounds. December 15, 2003.
36. The Value of Surgery Following Chemoradiation for Patients with Esophageal Cancer. Presented at
the Southern Association of Oncology Annual Meeting. Amelia Island, FL, August 8, 2004.
37. The Role of Tri-Modality in Patients Presenting with Esophageal Cancer. Presented at American
Association of Thoracic Surgery Annual Meeting. Toronto, Canada, April 24, 2004.
38. The Use of Concurrent Chemotherapy and Radiation Therapy in the Management of Head and Neck
Cancer Patients, Philadelphia Area Radiation Oncology Resident Review, April 28, 2004. Moderator
Scientific Session on Coronary and Cerebra-Vascular Radiation. Presented at the 46th Annual
Meeting of the American Society for Therapeutic Radiology and Oncology. Atlanta, GA, October 6,
2004.
39. The Evolving Role of Radiation Therapy in the Management of Head and Neck Cancer, Visiting
Professor, Hahnemann School of Medicine, Drexel University, Department of Radiation Oncology.
October 28, 2004.
40. Trimodality Therapy in Esophageal Cancer, Visiting Professor, Weill Medical College of Cornell
University, Department of Radiation Oncology, May 19, 2005
41. Future Directions in Esophageal Cancer, Visiting Professor, Emory University School of Medicine,
March 24, 2005.
42. A Phase II Trial Evaluating the Efficacy of Weekly Cetuximab, Paclitaxol, Carboplatin and Daily RT in
Esophageal Cancer. Presented at the 48th Annual Meeting of the American Society for Therapeutic
Radiology and Oncology (ASTRO). Philadelphia, PA. November 2006.
43. Clinical Utilization of IMRT in Head and Neck Cancer. Panel Discussion, IMRT/Physics/Radiobiology
Dose Effect. Presented at the 49th Annual Meeting of the American Society for Therapeutic
Radiology and Oncology. Los Angeles, CA., October 2007.
44. Innovations in Head and Neck Radiotherapy, a multidisciplinary discussion. Presented at the annual
meeting of the American College of Surgeons 2007, Chicago, IL.
45. The Current Role of Tri-Modality Therapy in Stage III Non-Small Cell Lung Cancer. Moderator Educational Session. Presented at the 50th Annual Meeting of the American Society for Therapeutic
Radiology and Oncology. Boston, MA., September 2008.
46. Challenging Cases in Esophageal and Gastric Cancer. Multi-Disciplinary Panel. Presented at the
2009 Gastrointestinal Cancers Symposium. American Society of Clinical Oncology. San Francisco,
CA, January 2009.
47. Neoadjuvant versus Adjuvant Chemotherapy and Radiation for Esophagogastric Cancers: Do the
Results of Recent Trials Give us a Direction. Presented at ASCO 2010 Annual Meeting. Chicago,
IL., June, 2010.
48. A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and Full Dose Radiotherapy
(XRT) followed by Resection and Consolidative Therapy for LA-NSCLC. Presented at the 51st Annual
Meeting of the American Society for Therapeutic Radiology and Oncology. San Francisco, CA,
November 2010.
22
LOCAL PRESENTATIONS – INVITED SPEAKER
1. Preliminary Results of I125 Implantation for Early Stage Prostate Cancer: The University of Maryland
Experience: Presented at the National Cancer Institute Radiation Oncology Grand Rounds.
Bethesda, MD, December 9, 1992.
2. The Use of Radiotherapy in the Management of Early Stage Glottic Carcinoma. Presented at Ground
Rounds in the Department of Radiation Oncology, University of Maryland. Baltimore, MD, June 1994.
3. Future Trends in the Management of Esophageal Cancers. Presented at Ground Rounds in the
Department of Radiation Oncology, University of Maryland. Baltimore, MD, September 1995.
4. The Emerging Role of Brachytherapy in the Treatment of Cholangiocarcinoma. Presented at the
Seminars in Liver Diseases at Camden Yards by Invitation of the Liver Center at the University of
Maryland Medical Center. Baltimore, MD, April 13, 1996.
5. Review of Current RTOG Head and Neck Protocols. Presented at Ground Rounds in the
Hematology/Medical Oncology Conference, University of Maryland Cancer Center. Baltimore, MD,
May 6, 1996.
6. Conformal Radiation Therapy. Presented at the University of Maryland Cancer Center Spring
Conference on Advances in Cancer Care. Berkeley Springs, WV, June 14-15, 1996.
7. The Role of Brachytherapy in the Prevention of Coronary Artery Restenosis. Presented at Medical
Ground Rounds for the School of Medicine, University of Maryland, Department of Medicine.
Baltimore, MD, November 5, 1997.
8. Multidisciplinary Treatment of Non-Small Cell Lung Cancer. Presented at the University of Maryland
CME Program. Baltimore, MD, October 21, 1999.
9. Chemo-Radiation Prior to Surgical Resection for Patients Presenting with Advanced Non-Small Cell
Cancers of the Lung. Presented at the Symposium for Thoracic Diseases Multi-Disciplinary
Conference. Baltimore, MD, December 7, 1999.
10. Innovations in Radiation Oncology. Presented at the Greenebaum Cancer Center Program in
Oncology, Cancer Update 2000. Baltimore, MD, November 17, 2000.
11. Combined Modality Therapy for Patients Presenting with Locally Advanced, Non-Small Cell Lung
Cancer. Presented at the Thoracic Diseases in the New Millennium Multidisciplinary Conference.
Baltimore, MD, December 7, 2001.
12. The Role of Radiation Therapy in the Management of Patients Presenting with Non-Small Cell Lung
Cancer. Presented at The Johns Hopkins Lung Cancer Symposium. Baltimore, MD, November 14,
2003.
13. The Role of Tri-Modality Therapy in the Management of Esophageal Carcinoma. Presented at the
Symposium for Thoracic Diseases Multidisciplinary Conference. Baltimore, MD, December 12, 2003.
14. Future Directions in the Management of Head and Neck Cancer Patients. Presented at Oncology
Ground Rounds, The Reading Hospital. Reading, VA, September 8, 2004.
15. Results of High Dose Chemotherapy for Esophageal Cancer. Presented at the Symposium for
Thoracic Diseases Multidisciplinary Conference. Baltimore, MD, December 3, 2004.
16. Radiotherapy Techniques for Esophageal Cancer. Presented at the Symposium for Thoracic
Diseases Multidisciplinary Conference, Baltimore, MD, October 24, 2008.
17. Changing the Treatment Paradigm for Head & Neck Cancer: The Implications of Biomarkers and
HPV. Grand Rounds, Robert W. Johnson Medical Center. New Brunswick, NJ, December 2011.
23
NATIONAL ORAL PRESENTATIONS
1.
Important Predictors of Response Determined by Surgical Stating Prior to Triple Modality Therapy
for Esophageal Cancer. Presented to the 39th Annual Scientific Meeting of the American Society
for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL, October 19-22, 1997.
2.
The Use of Concurrent Chemotherapy and Radiation Prior to Surgical Resection in Patients
Presenting with Apical Sulcus Tumors. Presented at the 82 nd Annual Meeting of the American
Radium Society, London, England, April 1-5, 2000.
3.
Clinical Outcomes and Dose Analysis of the Effect of Beta Radiation for the Management of In-Stent
Restenosis: Results of the Stents and Radiation Therapy Randomized Trial (START), Presented
At the 42nd Annual Scientific Meeting of the American Society for Therapeutic Radiology and
Oncology (ASTRO), Boston, MA, October 21-25, 2000.
4.
Combination of Adenovirus p16 (INK4A) Gene Therapy and Ionizing Radiation for Squamous Cell
Carcinomas of the Head and Neck. Presented at the Head and Neck Poster Discussion session at
the 42nd Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology,
October 21-25, 2000.
5.
Patient and Personnel Radiation Exposure During Intravascular Brachytherapy:
A Single Institutional Experience with Strontium-90 Isotope, presented at the American Heart
Association Meeting, New Orleans, LA, November 15, 2000.
6.
The Importance of Accurate Lymph Node Assessment Prior to Tri-Modality Therapy in Patients
Presenting with Esophageal Cancer, presented at the 83rd Annual American Radium Society, San
Diego, CA. April 25-29, 2001.
7.
Analysis of Clinical Outcomes from the START and START 40 Trials: The Efficacy of Sr-90
Radiation in the Treatment of Long Lesion In Stent Restenosis. Presented at the 43 rd Annual
Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, San Francisco,
CA, November 7, 2002.
8.
The National Standards of Practice for Patients Receiving Radiation Therapy for Carcinoma of the
Esophagus: Results of the 1996-1999 Patterns of Care Study. Accepted for Oral Presentation at
the 44th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology,
New Orleans, LA, October 9, 2002.
9.
Outcome Results of the 1996-1999 Patterns of Care Survey of the National Practice for Patients
Receiving Radiation Therapy for Carcinoma of the Esophagus. Presented at the 44 th Annual
Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, Salt Lake City,
UT, October 22, 2003.
10. Staging of Esophageal Cancer in Patients Treated with Initial Chemoradiation: Findings of the
Patterns of Care Study (PCS). Presented at the 45th Annual Scientific Meeting of the American
Society for Therapeutic Radiology and Oncology, Atlanta, GA, October 5, 2004.
11. Long-Term Clinical Follow-Up of the Phase III Randomized Trial (START) Evaluating the Role of
Beta Radiation for the Treatment of In-Stent Restensosis. Presented at the 45th Annual Scientific
Meeting of the American Society for Therapeutic Radiology and Oncology, Denver, CO,
October 17, 2005.
12. A Phase II Trail Evaluating the Efficacy of Weekly Cetuximab, Paclitaxol, Carboplatin and Daily RT
in Esophageal Cancer. Presented at the 46th Annual Scientific Meeting of the American Society for
Therapeutic Radiology and Oncology, Philadelphia, PA, November 6, 2006.
24
NATIONAL ORAL PRESENTATIONS – Continued
13. GCC 0442: A Phase II Trial Evaluating the Efficacy of Weekly Cetuximab, Paclitaxel, Carboplatin
and Daily RT in Locally Advanced SCCHN. Presented at the ASTRO’s Multidisciplinary Head and
Neck Symposium, Palm Springs, CA, January 18 - 20, 2007.
25